Mechanisms underlying differential effectiveness of memantine and ketamine in rapid antidepressant responses
Open accessThe DOI matches its Crossref record; 31 of the 31 references it cites were found in a registry or an index.
Abstract
Significance: Ketamine is an NMDA receptor (NMDAR) antagonist that elicits rapid antidepressant responses in patients with treatment-resistant depression. However, ketamine can also produce adverse side effects, which raised interest in whether the clinically tolerated NMDAR antagonist memantine can elicit similar fast antidepressant action. Rather surprisingly, clinical data have shown that memantine does not trigger rapid antidepressant effects for reasons that have yet to be elucidated. Here, we reconstitute the ketamine and memantine clinical findings in animal models and, combined with the analysis of synaptic function and subsequent intracellular signaling, demonstrate significant differences between the efficacies of ketamine and memantine on NMDAR-mediated neurotransmission and downstream intracellular signaling. These findings suggest a potential mechanism to explain the earlier clinical observations.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The cited source says what the claim attributes to it.
In the citing paper
“This differential effect of ketamine and memantine extended to intracellular signaling coupled to spontaneous NMDA receptors, in that memantine does not inhibit eEF2K nor alter BDNF protein expression in the hippocampus, key determinants of ketamine mediated rapid antidepressant effects (Gideons et al., 2014).”
From BDNF - a key transducer of antidepressant effects (2016) · cites this paper as Gideons et al., 2014
The cited source says what the claim attributes to it.
In the citing paper
“Work done in our laboratory demonstrated that memantine has little effect on the function of NMDA receptors activated by spontaneous neurotransmitter release, in contrast to ketamine.”
From BDNF - a key transducer of antidepressant effects (2016) · cites this paper as Gideons et al., 2014
The cited source says what the claim attributes to it.
In the citing paper
“In contrast, memantine, a non-competitive NMDAR channel blocker, failed to exert antidepressant actions in animal tests 64 and in humans 65–67, and which was suggested to be because memantine does not block NMDAR-mEPSCs under physiological Mg2+ levels 64.”
From Mechanisms of ketamine action as an antidepressant (2018) · cites this paper as [64]
The cited source says what the claim attributes to it.
In the citing paper
“Importantly, ketamine’s inhibition of NMDAR-mEPSCs occurs at physiological levels of Mg2+, an effect that was associated with the rapid antidepressant behavioral actions of ketamine 64.”
From Mechanisms of ketamine action as an antidepressant (2018) · cites this paper as [64]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Antidepressant effects of ketamine in depressed patients
Berman, R. M., Cappiello, A., Anand, A., Oren, D. A., Heninger, G. R., Charney, D. S., & Krystal, J. H. (2000) · Biological Psychiatry · doi:10.1016/s0006-3223(99)00230-9 · Cited by 3,856
A randomized trial of an N-methyl-D-aspartate antagonist in treatment-resistant major depression.
Zarate, C. A., Singh, J. B., Carlson, P. J., Brutsche, N. E., Ameli, R., Luckenbaugh, D. A., Charney, D. S., & Manji, H. K. (2006) · Archives of General Psychiatry · doi:10.1001/archpsyc.63.8.856 · Cited by 3,766
mTOR-Dependent Synapse Formation Underlies the Rapid Antidepressant Effects of NMDA Antagonists
Li, N., Lee, B., Liu, R.-J., Banasr, M., Dwyer, J. M., Iwata, M., Li, X.-Y., Aghajanian, G., & Duman, R. S. (2010) · Science · doi:10.1126/science.1190287 · Cited by 2,881 · cited 1×
“The rapid antidepressant effects of ketamine have also been suggested to be mediated by mammalian target of rapamycin (mTOR)-dependent synapse formation, although it remains unclear how blockade of the NMDAR activates mTOR (30).”
BackgroundNMDA receptor blockade at rest triggers rapid behavioural antidepressant responses
Autry, A. E., Adachi, M., Nosyreva, E., Na, E. S., Los, M. F., Cheng, P.-F., Kavalali, E. T., & Monteggia, L. M. (2011) · Nature · doi:10.1038/nature10130 · Cited by 1,926 · cited 10×
“In recent work, we demonstrated that the fast-acting antidepressant effect of ketamine requires deactivation of eukaryotic elongation factor 2 kinase (eEF2K) and subsequent desuppression of BDNF protein translation in the hippocampus (8, 9).”
BackgroundMethodResultSelf-citationMaeng, S., Zarate, C. A., Du, J., Schloesser, R. J., McCammon, J., Chen, G., & Manji, H. K. (2008) · Biological Psychiatry · doi:10.1016/j.biopsych.2007.05.028 · Cited by 1,103 · cited 1×
“In all experiments, we included a ketamine group as a direct comparison, which has previously been shown to elicit an antidepressant response in mice 30 min after administration without effects on locomotor activity at this time point (8, 9, 14, 15).”
MethodParsons, C. G., Danysz, W., & Quack, G. (1999) · Neuropharmacology · doi:10.1016/s0028-3908(99)00019-2 · Cited by 878 · cited 2×
“Pharmacol Biochem Behav 53(4): 791–797.”
BackgroundExcitatory glycine receptors containing the NR3 family of NMDA receptor subunits
Chatterton, J. E., Awobuluyi, M., Premkumar, L. S., Takahashi, H., Talantova, M., Shin, Y., Cui, J., Tu, S., Sevarino, K. A., Nakanishi, N., et al. (2002) · Nature · doi:10.1038/nature715 · Cited by 694 · cited 1×
“Additionally, it seems unlikely that any differences found between ketamine and memantine would be mediated by GluN3 containing NMDARs, because they do not show significant sensitivity to blockade by Mg or use dependent blockers (23, 24).”
BackgroundSutton, M. A., Ito, H. T., Cressy, P., Kempf, C., Woo, J. C., & Schuman, E. M. (2006) · Cell · doi:10.1016/j.cell.2006.03.040 · Cited by 633 · cited 1×
“Blockade of NMDAR-mEPSCs has been linked to the control of dendritic protein translation by decreasing calcium influx through the NMDAR into the synapse, leading to decreased phosphorylation of eEF2 by eEF2K and desuppression of protein translation (10, 12), thus providing a potential mechanism for A”
BackgroundPrice, R. B., Nock, M. K., Charney, D. S., & Mathew, S. J. (2009) · Biological Psychiatry · doi:10.1016/j.biopsych.2009.04.029 · Cited by 600
Voltage dependence of NMDA-activated macroscopic conductances predicted by single-channel kinetics
Jahr, C., & Stevens, C. (1990) · The Journal of Neuroscience · doi:10.1523/jneurosci.10-09-03178.1990 · Cited by 564
Cited by
Items 101–200 of 230
Crivellaro, G., Tottene, A., Vitale, M., Melone, M., Casari, G., Conti, F., Santello, M., & Pietrobon, D. (2021) · Neurobiology of Disease · doi:10.1016/j.nbd.2021.105419 · Cited by 37
“Interestingly, in contrast with high-affinity open channel blockers, memantine at low therapeutic doses has been reported to preferentially block extrasynaptic NMDARs while relatively sparing synaptic NMDARs (Xia et al., 2010; Gideons et al., 2014; Johnson et al., 2015).”
Zanos, P., Moaddel, R., Morris, P. J., Georgiou, P., Fischell, J., Elmer, G. I., Alkondon, M., Yuan, P., Pribut, H. J., Singh, N. S., et al. (2017) · Nature · doi:10.1038/nature22085 · Cited by 34
Chang, C., Su, C.-L., & Gean, P. (2018) · Neuropharmacology · doi:10.1016/j.neuropharm.2018.09.019 · Cited by 36
“On the other hand, ketamine, a NMDAR antagonist, exhibits a fast-acting antidepressant effect by reducing eEF2 phosphorylation and releasing the suppression of the synaptic protein translation of brain-derived neurotrophic factor (BDNF) (Autry et al., 2011; Gideons et al., 2014; Zunszain et al., 2013).”
How do serotonergic psychedelics treat depression: The potential role of neuroplasticity
Artin, H., Zisook, S., & Ramanathan, D. (2021) · World Journal of Psychiatry · doi:10.5498/wjp.v11.i6.201 · Cited by 33
Tse, Y. C., Lopez, J., Moquin, A., Wong, S.-M. A., Maysinger, D., & Wong, T. P. (2019) · Neuropsychopharmacology · doi:10.1038/s41386-019-0325-8 · Cited by 32
Duque, M., Chen, A., Hsu, E. T., Narayan, S., Rymbek, A., Begum, S., Saher, G., Cohen, A. E., Olson, D. E., Li, Y., et al. (2024) · Neuron · doi:10.1016/j.neuron.2024.11.011 · Cited by 34
Brain FNDC5/Irisin Expression in Patients and Mouse Models of Major Depression
Lima‐Filho, R. A. S., Fortuna, J. T. S., Cozachenco, D., Isaac, A. R., Silva, N. M. L. E., Saldanha, A., Santos, L. E., Ferreira, S. T., Lourenco, M. V., & Felice, F. G. D. (2023) · eNeuro · doi:10.1523/eneuro.0256-22.2023 · Cited by 34
“We note that the doses and durations of treatment we used for each compound have been previously reported to be compatible with their neuromodulatory activities in mice (Gideons et al., 2014; Duque et al., 2016; Halliday et al., 2017; Browne et al., 2018).”
BackgroundMethodDrewniany, E., Han, J., Hancock, C., Jones, R. L., Lim, J., Gorgani, N. N., Sperry, J., Yu, H. J., & Raffa, R. B. (2014) · Journal of Clinical Pharmacy and Therapeutics · doi:10.1111/jcpt.12238 · Cited by 34
“Investigation of this notable difference(39) led to the finding that ketamine, but not memantine augments BDNF protein expression, which is proposed to relate to ketamine’s rapid antidepressant effect.(39) BDNF is reduced in patients with MDD and BDNFdeficient mice are depressive-like in some behavioural tests,(40) bu…”
BackgroundGlasgow, N. G., Wilcox, M. R., & Johnson, J. W. (2018) · Neuropharmacology · doi:10.1016/j.neuropharm.2018.05.017 · Cited by 32
“As a result, our ability to predict how organic NMDAR channel blockers act at NMDARs under physiological conditions, which may depend importantly on the effects of a physiological Mg2þ concentration (Gideons et al., 2014), is limited.”
Emnett, C. M., Eisenman, L. N., Jayaram, M., Taylor, A., Doherty, J., Paul, S. M., Zorumski, C. F., & Mennerick, S. J. (2015) · British Journal of Pharmacology · doi:10.1111/bph.13007 · Cited by 34
“A recent study showed ketamine blocks spontaneous NMDA receptor miniature EPSCS more than memantine, but only in the presence of physiological magnesium (Gideons et al., 2014).”
BackgroundON or OFF?: Modulating the N-Methyl-D-Aspartate Receptor in Major Depression
Chan, S. Y., Matthews, E., & Burnet, P. W. J. (2017) · Frontiers in Molecular Neuroscience · doi:10.3389/fnmol.2016.00169 · Cited by 35
“Moreover, memantine neither induced eEF2 de-phosphorylation nor increased BDNF expression (Gideons et al., 2014), and its activity is not affected by mTOR inhibition (Sabino et al., 2013).”
InfluentialWei, M.-D., Wang, Y., Lu, K., Lv, B.-J., Wang, Y., & Chen, W. (2019) · Behavioural Brain Research · doi:10.1016/j.bbr.2019.112342 · Cited by 32
Lester, H. A., Lavis, L. D., & Dougherty, D. A. (2015) · American Journal of Psychiatry · doi:10.1176/appi.ajp.2015.14121537 · Cited by 30
“Many other experiments show that BDNF is released during antidepressant action.”
BackgroundInfluentialRibeiro, A. C. R., Zhu, J., Kronfol, M. M., Jahr, F. M., Younis, R. M., Hawkins, E., McClay, J. L., & Deshpande, L. S. (2020) · NeuroToxicology · doi:10.1016/j.neuro.2020.06.011 · Cited by 32
Potential of Glutamate-Based Drug Discovery for Next Generation Antidepressants
Chaki, S., & Fukumoto, K. (2015) · Pharmaceuticals · doi:10.3390/ph8030590 · Cited by 35
“Interestingly, memantine and ketamine were recently shown to have different NMDA receptor function blocking abilities under physiological concentrations of Mg2+, at which ketamine effectively blocks the NMDA receptor while memantine has a negligible effect [50].”
BackgroundMichaëlsson, H., Andersson, M., Svensson, J., Karlsson, L., Ehn, J., Culley, G., Engström, A., Bergström, N., Savvidi, P., Kuhn, H., et al. (2019) · Acta Physiologica · doi:10.1111/apha.13211 · Cited by 28
“Despite their difference in NMDAR desensitization,(105) memantine is also potentially antidepressant.(19) However, such specificity might, at least partly, explain the antidepressant actions of ketamine with more limited(106) effects of other open‐channel blockers such as MK‐801.”
BackgroundMethodResultInfluentialZhu, J., Hawkins, E., Phillips, K., & Deshpande, L. S. (2020) · International Journal of Environmental Research and Public Health · doi:10.3390/ijerph17134710 · Cited by 27
A key requirement for synaptic Reelin signaling in ketamine-mediated behavioral and synaptic action
Kim, J., Herz, J., Kavalali, E. T., & Monteggia, L. M. (2021) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.2103079118 · Cited by 30
Self-citationOrtiz, V., Campos, R. C., Fofo, H., Fernández, S. P., & Barik, J. (2022) · Neuropsychopharmacology · doi:10.1038/s41386-022-01314-4 · Cited by 32
“Indeed, ketamine increased stress coping in antidepressantpredictive procedures such as the forced swim test [51], the novelty-suppressed feeding [52], and learned helplessness [53].”
BackgroundRéus, G. Z., Nacif, M., Abelaira, H. M., Tomaz, D. B., Santos, M. A., Carlessi, A. S., Matias, B. I., da Luz, J. R., Steckert, A. V., Jeremias, G. C., et al. (2015) · Current Neurovascular Research · doi:10.2174/1567202612666150122122924 · Cited by 28
Urethane anesthesia suppresses hippocampal subthreshold activity and neuronal synchronization
Yagishita, H., Nishimura, Y., Noguchi, A., Shikano, Y., Ikegaya, Y., & Sasaki, T. (2020) · Brain Research · doi:10.1016/j.brainres.2020.147137 · Cited by 31
Translational Assessments of Reward Responsiveness in the Marmoset
Wooldridge, L. M., Bergman, J., Pizzagalli, D. A., & Kangas, B. D. (2020) · The International Journal of Neuropsychopharmacology · doi:10.1093/ijnp/pyaa090 · Cited by 28
“, 1991), but not ketamine (Liu et al., 2001; Gideons et al., 2014), to antagonize NMDA receptor function, suggesting that ketamine acts more robustly than phencyclidine during periods of low neuronal activity.”
BackgroundKetamine: A Neglected Therapy for Alzheimer Disease
Smalheiser, N. R. (2019) · Frontiers in Aging Neuroscience · doi:10.3389/fnagi.2019.00186 · Cited by 29
Waller, J. A., Chen, F., & Sánchez, C. (2016) · Neuropharmacology · doi:10.1016/j.neuropharm.2015.12.012 · Cited by 25
Innovations in the delivery of exposure and response prevention for obsessive-compulsive disorder
Patel, S. R., Comer, J., & Simpson, H. B. (2021) · Current Topics in Behavioral Neurosciences · doi:10.1007/7854_2020_202 · Cited by 24
Ketamine induces immediate and delayed alterations of OCD-like behavior
Thompson, S. L., Welch, A. C., Iourinets, J., & Dulawa, S. C. (2020) · Psychopharmacology · doi:10.1007/s00213-019-05397-8 · Cited by 24
Sustainable manganese catalysis for late-stage C–H functionalization of bioactive structural motifs
Son, J. (2021) · Beilstein Journal of Organic Chemistry · doi:10.3762/bjoc.17.122 · Cited by 26
Astrocytic Na+, K+ ATPases in physiology and pathophysiology
Pietrobon, D., & Conti, F. (2024) · Cell Calcium · doi:10.1016/j.ceca.2024.102851 · Cited by 23
The Ketamine Antidepressant Story: New Insights
Alshammari, T. K. (2020) · Molecules · doi:10.3390/molecules25235777 · Cited by 23
“Memantine was found to lack the modulation capacity ketamine has in eEF2K, suggesting that eEF2K is a key element in mediating the rapid antidepressant effects of ketamine [89].”
BackgroundKetamine induced synaptic plasticity operates independently of long-term potentiation
Piazza, M. K., Kavalali, E. T., & Monteggia, L. M. (2024) · Neuropsychopharmacology · doi:10.1038/s41386-024-01895-2 · Cited by 25
Self-citationChoudhury, A., Singh, S., Palit, G., Shukla, S., & Ganguly, S. (2015) · Behavioural Brain Research · doi:10.1016/j.bbr.2015.10.027 · Cited by 25
Antos, Z., Żukow, X., Bursztynowicz, L., & Jakubów, P. (2024) · International Journal of Molecular Sciences · doi:10.3390/ijms252413658 · Cited by 21
“Moreover, ketamine’s activity-independent blockade of NMDARs reduces phosphorylation of eukaryotic elongation factor 2 (eEF2), which, in turn, enhances BDNF expression and supports synaptic formation [92,93].”
New investigational agents for the treatment of major depressive disorder
Pochwat, B., Krupa, A. J., Siwek, M., & Szewczyk, B. (2022) · Expert Opinion on Investigational Drugs · doi:10.1080/13543784.2022.2113376 · Cited by 23
Zeng, J., Wang, Z., Zhang, X., Zhao, A., Qi, H., Jiang, Y., Cai, D., & Zeng, N. (2025) · Phytomedicine · doi:10.1016/j.phymed.2025.156927 · Cited by 23
Zhu, J., Cai, H., Yuan, Y., Yue, Y., Jiang, D., Chen, C., Zhang, W., Zhuo, C., & Yu, Y. (2018) · Brain Imaging and Behavior · doi:10.1007/s11682-018-9845-9 · Cited by 20
“However, emerging evidence has demonstrated that different drugs may trigger antidepressant responses in different ways (Gideons et al. 2014).”
BackgroundDisinhibition of somatostatin interneurons confers resilience to stress in male but not female mice
Jefferson, S. J., Feng, M., Chon, U., Guo, Y., Kim, Y., & Lüscher, B. (2020) · Neurobiology of Stress · doi:10.1016/j.ynstr.2020.100238 · Cited by 24
“Conversely, reduced p-eEF2 levels in male SSTCre:γ2f/f mice are consistent with reduced phosphorylation of eEF2 observed in ketamine treated male mice (Autry et al., 2011; Gideons et al., 2014).”
Lucido, M. J., & Dunlop, B. W. (2025) · Brain Sciences · doi:10.3390/brainsci15020161 · Cited by 24
“Ketamine has higher affinity relative to memantine for NMDARs containing the GluN2B/NR2B subunit [89], which is associated with basal levels of depression-like behavior in a mouse model [90].”
Biosensors Show the Pharmacokinetics of S-Ketamine in the Endoplasmic Reticulum
Bera, K., Kamajaya, A., Shivange, A. V., Muthusamy, A. K., Nichols, A. L., Borden, P. M., Grant, S. N., Jeon, J., Lin, E., Bishara, I., et al. (2019) · Frontiers in Cellular Neuroscience · doi:10.3389/fncel.2019.00499 · Cited by 22
“, 2014), eukaryotic elongation factor 2 (EEF2) kinase (Autry et al., 2011; Gideons et al., 2014; Adaikkan et al., 2018), serine/threonine kinase glycogen synthase kinase-3 (GSK-3; Beurel et al.”
BackgroundMancini, M., Ghiglieri, V., Bagetta, V., Pendolino, V., Vannelli, A., Cacace, F., Mineo, D., Calabresi, P., & Picconi, B. (2015) · Neuropharmacology · doi:10.1016/j.neuropharm.2015.10.015 · Cited by 18
Li, C., Chen, X., Chen, S.-M., Mu, R.-H., Liu, B., Luo, L., Liu, X., Geng, D., Liu, Q., & Yi, L. (2015) · Brain Research · doi:10.1016/j.brainres.2015.11.005 · Cited by 17
Interplay between Gating and Block of Ligand-Gated Ion Channels
Phillips, M. B., Nigam, A., & Johnson, J. W. (2020) · Brain Sciences · doi:10.3390/brainsci10120928 · Cited by 19
Antidepressant Actions of Ketamine: Potential Role of L-Type Calcium Channels
Robinson, B. L., Gu, Q., & Kanungo, J. (2021) · Chemical Research in Toxicology · doi:10.1021/acs.chemrestox.0c00411 · Cited by 18
Hasegawa, S., Yoshimi, A., Mouri, A., Uchida, Y., Hida, H., Mishina, M., Yamada, K., Ozaki, N., Nabeshima, T., & Noda, Y. (2018) · Neuropharmacology · doi:10.1016/j.neuropharm.2018.12.020 · Cited by 18
“) (Gideons et al., 2014; Li et al., 2010) and ifenprodil at 3 and 20mg/kg (i.”
Miquel-Rio, L., Sarriés-Serrano, U., Sancho‐Alonso, M., Florensa-Zanuy, E., Paz, V., Ruiz‐Bronchal, E., Manashirov, S., Campa, L., Pilar-Cuéllar, F., & Bortolozzi, A. A. (2024) · iScience · doi:10.1016/j.isci.2024.109787 · Cited by 15
The NMDA receptor subunit GluN2D is a potential target for rapid antidepressant action
Vestring, S., Veleanu, M., Perez, M. C., Schuberth, L. E., Bronnec, M., Li, A., Würz, L. M., Erdogdu, F., Stocker, J., Moos, J., et al. (2025) · Nature Communications · doi:10.1038/s41467-025-66774-w · Cited by 13
“Moreover, nonselective NMDAR inhibitors such as memantine do not exhibit antidepressant activity in rodent models or clinical trials 73 .”
Raab‐Graham, K. F., Workman, E. R., Namjoshi, S. V., & Niere, F. (2016) · Brain Research · doi:10.1016/j.brainres.2016.04.020 · Cited by 13
“…A uthor M anuscript A uthor M anuscript A uthor M anuscript resting NMDAR currents, whereas memantine only blocks NMDARs engaged in firing Remarkably, rodents treated with MK-801 display improvement on behavioral despairs, while with memantine they do not (Autry et al., 2011; Gideons et al., 2014).”
BackgroundHenderson, T. A. (2016) · Neural Regeneration Research · doi:10.4103/1673-5374.177708 · Cited by 13
“Other NMDAR antagonists, such as memantine, lack the antidepressant effects of ketamine and this difference appears to reflect ketamine’s distinct ability to inhibit the phosphorylation of eEF2 and upregulate the expression of BDNF (Gideons et al., 2014; Bjorholm and Manteggia, 2015).”
BackgroundEmnett, C. M., Li, H., Jiang, X., Benz, A. M., Boggiano, J., Conyers, S. B., Wozniak, D. F., Zorumski, C. F., Reichert, D. E. C., & Mennerick, S. J. (2016) · Scientific Reports · doi:10.1038/srep38808 · Cited by 14
Widman, A. J., & McMahon, L. L. (2020) · Advances in pharmacology · doi:10.1016/bs.apha.2020.05.001 · Cited by 15
Bentley, S., Artin, H., Mehaffey, E., Liu, F., Sojourner, K., Bismark, A. W., Printz, D., Lee, E., Martis, B., Peralta, S. D., et al. (2022) · Pharmacotherapy The Journal of Human Pharmacology and Drug Therapy · doi:10.1002/phar.2664 · Cited by 17
Astrocytic Glutamate Transporters and Migraine
Conti, F., & Pietrobon, D. (2022) · Neurochemical Research · doi:10.1007/s11064-022-03849-w · Cited by 14
“It is also consistent with the higher affinity for glutamate (and lower susceptibility to Mg block) of GluN1-N2B compared to other NMDA receptors, including the triheteromeric GluN1-N2A-N2B receptors [128, 129], which appear to be the main synaptic NMDARs at the L2/3 pyramidal cell synapses [122].”
BackgroundInfluentialZhang, N., Song, C., Zhao, B.-M., Xing, M., Luo, L., Gordon, M. L., & Cheng, Y. (2017) · Journal of Molecular Neuroscience · doi:10.1007/s12031-017-0974-1 · Cited by 12
“…diseases, such as enhancing endogenous self-repair potential of oligodendrocytes (Li et al. 2015), restoring myelin sheath formation (Mao et al. 2012), anti-excitotoxicity, and neuroprotection (Groger and Plesnila 2014; Trotman et al. 2015), and increasing cerebral blood flow (Kilic et al. 2013).”
BackgroundAlternatives to ketamine in depression: state-of-the-art and future perspectives
Jelen, L. A., King, S., & Stone, J. M. (2017) · Therapeutic Advances in Psychopharmacology · doi:10.1177/2045125317749456 · Cited by 12
Jiang, Y., Dong, Y., & Hu, H. (2024) · Philosophical Transactions of the Royal Society B Biological Sciences · doi:10.1098/rstb.2023.0225 · Cited by 16
“Second, for the same reason above, it will be more relevant to use animals in the depression-like state instead of the naive state to evaluate the antidepressant effects of NMDAR inhibitors, especially the use-dependent type inhibitors (e.g. memantine) [67].”
BackgroundKetamine in Clinical Practice: Transitioning from Anesthetic Agent to Psychiatric Therapeutic
Quintero, J.-M., Bustos, R., Lechtig, S., Beltran, S., & Zarate, C. A. (2025) · Cambridge University Press eBooks · doi:10.1017/9781009585330.007 · Cited by 13
Langreck, C. B., Chen, B. K., Luna, V. M., Nelson, M., Turi, G. F., Hill, R., Rubinstenn, G., Canals, M., Lane, J. R., Denny, C. A., et al. (2025) · Biological Psychiatry · doi:10.1016/j.biopsych.2025.07.004 · Cited by 12
Harraz, M. M., & Snyder, S. H. (2017) · Neurotherapeutics · doi:10.1007/s13311-017-0540-0 · Cited by 12
“Furthermore, memantine failed to inhibit the phosphorylation of eEF2 or upregulate brain-derived neurotrophic factor (BDNF) protein expression, which is crucial for ketamine’s antidepressant-like effect [21].”
Božić, M., Pirnat, S., Fink, K., Potokar, M., Kreft, M., Zorec, R., & Stenovec, M. (2023) · Cells · doi:10.3390/cells12101360 · Cited by 13
“Not only neurons and their glutamatergic NMDA receptors as ketamine targets [29], but also astrocytes have been considered a target of ketamine, where pleiotropic ketamine-mediated functional alterations have been reported including the inhibition of the vesicular secretion of peptides [30], very likely through the ke…”
BackgroundYao, H., Wang, X., Chi, J., Chen, H., Liu, Y., Jiayi, Y., Yu, J., Ruan, Y., Xiang, X., Pi, J., et al. (2024) · Molecules · doi:10.3390/molecules29050964 · Cited by 12
Mechanism-guided identification of antidepressant G protein-coupled receptor drug targets
Munguba, H., Arefin, A., Hasegawa, R., Posa, L., Romano, G. R., Peddada, T., Donatelle, A., Singh, A., Gutzeit, V. A., Vijay, A., et al. (2026) · Cell · doi:10.1016/j.cell.2026.04.006 · Cited by 12
Phencyclidine Disrupts Neural Coordination and Cognitive Control by Dysregulating Translation
Park, E., Kao, H., Jourdi, H., van Dijk, M. T., Segura-Carrillo, S., Tunnell, K. W., Gutierrez, J., Wallace, E. J. C., Regier, M., Radwan, B., et al. (2023) · Biological Psychiatry Global Open Science · doi:10.1016/j.bpsgos.2023.04.009 · Cited by 9
“While controversy persists over which translation pathways are more relevant for ketamine ’ s effects (20,22,81,82), the present fi ndings with AP5, MK-801, Ro25-6981, and NVP-AAM077 demonstrate that different NMDAR antagonists have different effects on translation and so different potential for…”
BackgroundEffects of Ketamine on Metabolomics of Serum and Urine in Cynomolgus Macaques (Macaca fascicularis).
Pan, X., Zeng, X., Hong, J., Yuan, C., Cui, L., Ma, J., Chang, Y. H., & Hua, X. (2016) · Europe PMC (PubMed Central) · Cited by 10
Wang, Y., Xu, J., Zhou, X., Che, L., Qiu, M., Liu, Y., Gao, M., & Yang, Z. (2025) · Advanced Science · doi:10.1002/advs.202516024 · Cited by 13
Duan, J., Lao, C., Chen, J., Pan, F., Zhang, C., Xu, W., Zhou, W., Hu, J., Shang, D., Huang, M., et al. (2018) · Neuropsychiatric Disease and Treatment · doi:10.2147/ndt.s160832 · Cited by 9
“16 However, there were a few studies that provided some evidences for the antidepressant role of memantine.”
Nguyen, T. M. L., Jollant, F., Tritschler, L., Colle, R., Corruble, E., & Gardier, A. M. (2023) · Pharmaceuticals · doi:10.3390/ph16040634 · Cited by 11
“Another NMDA-R antagonist, such as memantine, does not inhibit the phosphorylation of eukaryotic elongation factor-2 (eEF2) kinase or increase the BDNF protein expression, which are the essential determinants of ketamine-mediated antidepressant effects [119].”
Tsai, G. E. (2016) · Advances in pharmacology · doi:10.1016/bs.apha.2016.03.003 · Cited by 11
The therapeutic potential of psilocybin beyond psychedelia through shared mechanisms with ketamine
Park, D., Lee, G., Lee, W.-G., Kim, B. S., Lee, Y., & Kim, J. (2025) · Molecular Psychiatry · doi:10.1038/s41380-025-03100-2 · Cited by 14
Arrabal-Gómez, C., Beltran-Casanueva, R., Hernández-García, A., Bayolo-Guanche, J. V., Barbancho, M. Á., Serrano-Castro, P. J., & Narváez, M. (2024) · Cells · doi:10.3390/cells13080669 · Cited by 8
Acero-Castillo, M. C., Correia, M. B. M., Caixeta, F. V., Motta, V., Barros, M., & Maior, R. S. (2024) · Neuropharmacology · doi:10.1016/j.neuropharm.2024.110088 · Cited by 8
Synaptic basis of rapid antidepressant action
Kavalali, E. T., & Monteggia, L. M. (2024) · European Archives of Psychiatry and Clinical Neuroscience · doi:10.1007/s00406-024-01898-6 · Cited by 7
“…neurotransmission at near resting membrane potentials provided the motivation for the subsequent study to examine whether ketamine was effective in blocking these resting NMDA receptor mediated currents and whether there were any differences between the actions of ketamine and memantine [ 21 ].”
InfluentialSelf-citationPromises and Pitfalls of NMDA Receptor Antagonists in Treating Violent Aggression
Bartsch, C. J., & Nordman, J. C. (2022) · Frontiers in Behavioral Neuroscience · doi:10.3389/fnbeh.2022.938044 · Cited by 7
Belloch, F. B., Cortés-Erice, M., Herzog, É., Zhang, X. M., Diaz-Perdigón, T., Puerta, E., & Tordera, R. M. (2022) · Progress in Neuro-Psychopharmacology and Biological Psychiatry · doi:10.1016/j.pnpbp.2022.110640 · Cited by 8
Mario, A., Leccisotti, I., Claudia, M. M., Bellomo, A., Panza, F., Tommaso, C., & Madia, L. (2025) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2025.118199 · Cited by 9
Ketamine for acute catatonia: A case report
Kobayashi, B. (2021) · Current Psychiatry · doi:10.12788/cp.0132 · Cited by 8
Drugs and Endogenous Factors as Protagonists in Neurogenic Stimulation
Chiareli, R. A., Marques, B. L., Carvalho, G. A., Souza, R. T. V., Santana, P. H. G., Santiago, H. C., Pinto, M. C. X., Birbrair, A., Parreira, R. C., Ulrich, H., et al. (2022) · Stem Cell Reviews and Reports · doi:10.1007/s12015-022-10423-y · Cited by 5
Treatment for Alzheimer's diseases
Tyuvina, N. A., & Владимировна, Б. В. (2015) · Neurology neuropsychiatry Psychosomatics · doi:10.14412/2074-2711-2015-3-80-85 · Cited by 7
Wang, C.-M., Lin, Z.-H., Lin, Z.-Q., Yao, Q.-Y., & Zhang, Y.-F. (2018) · Journal of Psychopharmacology · doi:10.1177/0269881118812099 · Cited by 5
Segura, L., & Latanga, G. B. (2025) · Psychology and Education A Multidisciplinary Journal · doi:10.70838/pemj.430502 · Cited by 5
Phillips, M. B., Povysheva, N. V., Neureiter, E. G., Nigam, A., Hartnett, K. A., Hell, J. W., Aizenman, E., & Johnson, J. W. (2026) · Science Advances · doi:10.1126/sciadv.aec3154 · Cited by 6
“…inhibition of GluN2A-containing receptors by memantine under nonexcitotoxic conditions also may contribute to the weaker antidepressant effects of memantine compared to ketamine: The antidepressant actions of ketamine have been linked to inhibition of GluN2A-containing NMDARs ( 92 , 98 , 99 ).”
Schnell wirksame Antidepressiva – neurobiologische Wirkprinzipien
Gass, P., Vasilescu, A.-N., & Inta, D. (2021) · Der Nervenarzt · doi:10.1007/s00115-021-01225-7 · Cited by 6
“Der für die Behandlung der AlzheimerErkrankung zugelassene NMDA-RezeptorAntagonist Memantin zeigte in mehreren klinischen Studien keine antidepressive Wirkung, möglicherweise, weil die Substanz eine geringere Affinität, eine geringere Verweildauer im Ionenkanal oder geringere blockierende Eigenschaften aufweist [13].”
BackgroundAge-related impairment in fear memory extinction is restored by ketamine in middle-aged mice
Zhao, Y., Shao, H., Wang, H., Li, H., & Xue, Q. (2023) · Cognitive Affective & Behavioral Neuroscience · doi:10.3758/s13415-023-01118-z · Cited by 5
“Ketamine, a noncompetitive antagonist of the N-methylD-aspartate receptor, has received increasing attention because of its rapid antidepressant effect (Autry et al., 2011; Gideons et al., 2014; Yang et al., 2018; Zarate et al., 2006).”
BackgroundLi, J., Wang, Y., Zhang, Y., Liu, M., Rong, X., & Jiang, J. (2024) · Frontiers in Pharmacology · doi:10.3389/fphar.2024.1476558 · Cited by 8
Camacho, M. B., Vijitbenjaronk, W. D., & Anastasio, T. J. (2019) · Frontiers in Pharmacology · doi:10.3389/fphar.2019.01215 · Cited by 5
La kétamine : un neuropsychotrope au mécanisme d’action innovant
Guilloux, J., Nguyen, T. M. L., & Gardier, A. M. (2023) · Biologie Aujourd hui · doi:10.1051/jbio/2023026 · Cited by 5
Pochwat, B. (2022) · Psychiatria Polska · doi:10.12740/pp/onlinefirst/134330 · Cited by 4
MeCP2 prevents against sustained ketamine-induced synaptic depression at inhibitory synapses
Piazza, M. K., Weit, A. R., Kavalali, E. T., Neul, J. L., & Monteggia, L. M. (2025) · iScience · doi:10.1016/j.isci.2025.112485 · Cited by 3
“46 Therefore, we hypothesized that BDNF-TrkB signaling may play a key role in the differences observed following ketamine and memantine’s effects on inhibitory synapses in WT and KO mice.”
Self-citationArena, Á. R., Rubinstein, M. R., Genaro, A. M., Tifner, V., Risnik, D., López-Carvajal, J. E., Daray, F. M., Silva, E. A. C., & Errasti, A. E. (2025) · Molecular Psychiatry · doi:10.1038/s41380-025-03338-w · Cited by 6
Yaprak, G., Çini, N., Atasoy, Ö., Uyanıkgil, Y., Erdoğan, M. A., & Erbaş, O. (2024) · Radiation and Environmental Biophysics · doi:10.1007/s00411-024-01085-0 · Cited by 3
“The impact of ketamine administration on BDNF levels were also examined in Alzheimer's disease and treatment-resistant depression models and its benefit in potentiation of the expression of BDNF was shown (Gideons et al. 2014; Smalheiser 2019; Chang et al. 2019; Lara et al. 2013; Zhang and Ho 2016).”
Voldřich, J., Matoušová, M., Šmídková, M., Slavíková, B., Chodounská, H., Kudová, E., & Mertlíková‐Kaiserová, H. (2022) · European Journal of Pharmacology · doi:10.1016/j.ejphar.2022.175056 · Cited by 3
Linkovski, O., Wheaton, M. G., Zwerling, J., Odgerel, Z., van Roessel, P., Filippou-Frye, M., Lombardi, A., Wright, B., Steinman, S. A., Simpson, H. B., et al. (2018) · Journal of Clinical Psychopharmacology · doi:10.1097/jcp.0000000000000994 · Cited by 3
Dysregulated Protein Synthesis in Major Depressive Disorder
Heaney, C. F., & Raab‐Graham, K. F. (2019) · Oxford University Press eBooks · doi:10.1093/oxfordhb/9780190686307.013.3 · Cited by 4
Kim, J., Kleinfelter, B., Kavalali, E. T., & Monteggia, L. M. (2024) · Neuropsychopharmacology · doi:10.1038/s41386-024-01908-0 · Cited by 3
Self-citationMacedo, B. L., Veloso, M. D., Dias, I. B., Ayub, J. G. M., & Beijamini, V. (2023) · Behavioural Brain Research · doi:10.1016/j.bbr.2023.114834 · Cited by 3
Ketamine Treatment for Mood Disorders
Klise, A., Lerner, B. S., Ettensohn, M. F., & Levine, S. P. (2018) · Psychiatric Annals · doi:10.3928/00485713-20180315-01 · Cited by 2
Doan, J., Defaix, C., Mendez‐David, I., Gardier, A. M., Colle, R., Corruble, E., McGowan, J. C., David, D. J. P., Guilloux, J., & Tritschler, L. (2023) · Fundamental and Clinical Pharmacology · doi:10.1111/fcp.12917 · Cited by 2
“Likewise, an acute administration of several NMDA receptor antagonists, including ketamine or its metabolite (2 R ,6 R )-hydroxynorketamine (HNK), or Ro25-6981, promoted antidepressant-like activities [24, 44, 45], notably in the NSF [45, 46].”
BackgroundChen, S., Cheng, W., Chao, C.-C., Kuo, C.-H., & Liao, R. (2024) · Pharmacology Biochemistry and Behavior · doi:10.1016/j.pbb.2024.173904 · Cited by 2
Distinct Roles of NMDA Receptor GluN2 Subunits in the Effects of Ketamine and Its Enantiomers
Ide, S., & Ikeda, K. (2020) · Springer eBooks · doi:10.1007/978-981-15-2902-3_10 · Cited by 2
Chapter 52. Treatment of Obsessive-Compulsive Disorder
Kayser, R. R., & Simpson, H. B. (2024) · American Psychiatric Association Publishing eBooks · doi:10.1176/appi.books.9781615375523.as52 · Cited by 1
Özler, C., Özkan, E., Shomalizadeh, N., Kesibi, J., Sapancı, S., Akpunar, F., Uçar, E. A., & Özdemir, Y. (2025) · Experimental Brain Research · doi:10.1007/s00221-025-07085-w · Cited by 1
“Ketamine’s rapid-acting, robust, and per - sistent antidepressant-like effects aren’t observed in other NMDAR antagonists such as MK-801 and memantine (de Bartolomeis et al. 2013; Gideons et al. 2014 ).”
Hunt, M. J., & Wróbel, J. (2025) · Journal of Psychopharmacology · doi:10.1177/02698811251352454 · Cited by 1
“This is also supported by studies showing memantine, which does not share ketamine’s antidepressant effects (Gideons et al., 2014), only weakly affects HFO in the brains of experimental animals (Hiyoshi et al., 2014; Mao et al., 2020).”
Metadata
- Authors
- Gideons, E. S., Kavalali, E. T., & Monteggia, L. M.
- Affiliations
- The University of Texas Southwestern Medical Center (US)
- Venue
- Proceedings of the National Academy of Sciences
- Publisher
- National Academy of Sciences
- Published
- 2014-05-27
- Volume
- 111
- Issue
- 23
- Pages
- 8649-8654
- ISSN
- 0027-8424 (ISSN-L)
- 1091-6490
- PMC
- PMC4060670
- OpenAlex
- W2033919519
- Cited by
- 232
- References
- 31
- Citations by year
- 2026: 6 · 2025: 16 · 2024: 15 · 2023: 13 · 2022: 14 · 2021: 16 · 2020: 24 · 2019: 20 · 2018: 23 · 2017: 21 · 2016: 29 · 2015: 24 · 2014: 11
- FWCI
- 20.59
- Type
- journal article
- Language
- en
- Open access
- green
- www.ncbi.nlm.nih.gov
- Locations
- Proceedings of the National Academy of Sciences (publishedVersion)
- Europe PMC (PubMed Central) (publishedVersion)
- PubMed Central (publishedVersion)
- PubMed (publishedVersion)
- Funders
- National Institute of Mental Health (MH 070727, R01MH066198, MH-066198, R01MH070727)
- National Institute of Neurological Disorders and Stroke (T32NS069562)
- Topics
- Health Sciences › Medicine › Pharmacology (medical) › Treatment of Major Depression
- Life Sciences › Neuroscience › Cellular and Molecular Neuroscience › Neuroscience and Neuropharmacology Research
- Health Sciences › Medicine › Psychiatry and Mental health › Electroconvulsive Therapy Studies
- Keywords
- ketamine, memantine, rapid antidepressant response, treatment-resistant depression, NMDA receptor antagonism, miniature excitatory postsynaptic currents, hippocampal neurons, BDNF expression, intracellular signaling, antidepressant mechanism
- MeSH terms
- Animals, Animals, Newborn, Antidepressive Agents, Cells, Cultured, Hippocampus, Humans, Ketamine, Magnesium, Male, Memantine, Mice, Inbred C57BL, Motor Activity, Neurons, Phosphorylation, Time Factors, Blotting, Western, Receptors, N-Methyl-D-Aspartate, Patch-Clamp Techniques, Excitatory Amino Acid Antagonists, Brain-Derived Neurotrophic Factor, Excitatory Postsynaptic Potentials, Peptide Elongation Factor 2, Mice
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.